Ventus Enters NLRP3 Inhibitor Race With Parkinson’s Candidate
Adds To Novo Nordisk Partnership
Tricky drug development challenges have held back the NLRP3 inhibitor field for decades but Ventus and its many rivals believe the class can deliver on its huge potential, from Parkinson’s disease to NASH and arthritis.
